Rani Therapeutics Holdings Inc

NASDAQ:RANIUnited States

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Contact Information

Headquarters

2051 Ringwood AvenueSAN JOSE, CA, United States 95131

Phone

408-457-3700

Fax

302-655-5049

Executives

Executive Chairman of the Board

Mir Imran

Chief Executive Officer, Director

Talat Imran

Chief Financial Officer

Svai Sanford

Chief Scientific Officer

Mir Hashim

General Counsel

Eric Groen